WuXi AppTec, a global pharmaceutical and medical device open-access capability and technology platform company, is expanding its facilities in San Diego.
The newly expanded facility will establish a center of excellence in screening, discovery biology, pharmacology, and small molecule process R&D, including phase I GMP manufacturing. It will provide key elements of WuXi’s small molecule capability and technology platform under one roof, enhancing services to North American pharmaceutical and biotech industries.
“This expansion will enable us to better serve our U.S. and global customers, and contribute to the growth and success of the dynamic San Diego biotech ecosystem,” said Dr. Ge Li, chairman and CEO of WuXi AppTec.
WuXi AppTec employs an estimated 1,700 employees in the U.S. In addition to San Diego, the company maintains domestic facilities and offices in Philadelphia, Atlanta, Austin, Cambridge, St. Paul, and Cranbury-Plainsboro, NJ. In total, it maintains 27 sites around the globe.
(Source: WuXi AppTec)
Filed Under: Drug Discovery
